ENCell Co

ENCell Co Assets per Share

The Total Assets per Share of ENCell Co (456070.KQ) as of Oct 26, 2026 is 7,244.71 KRW. In the previous year, Total Assets per Share was 6,338.69 KRW — a change of 14.29% (higher).

Assets per Share

7,244.71KRW

YoY

14.29%

Last updated:

Total Assets per Share of ENCell Co is 2025 7,244.71 KRW. Total Assets per Share of ENCell Co was 2024 6,338.69 KRW. It decreases by 14.29% higher compared to the previous year.

The ENCell Co Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2021
4,385.52 KRW
Jan 1, 2022
6,225.13 KRW
Jan 1, 2023
5,001.04 KRW
Jan 1, 2024
6,338.69 KRW
Jan 1, 2025
7,244.71 KRW
The ENCell Co Assets per Share history
YEARAssets per ShareYoY
7,244.71KRW+14.29%
6,338.69KRW+26.75%
5,001.04KRW-19.66%
6,225.13KRW+41.95%
4,385.52KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ENCell Co Stock analysis

What does ENCell Co do? ENCell Co Ltd generates revenue through the development and research of cell and gene-based biopharmaceuticals, offering biopharmaceutical quality testing services, and providing biopharmaceutical consignment production. The company serves pharmaceutical and biotechnology firms requiring advanced drug development solutions and quality assurance. Its primary focus is on cell and gene therapies, with services tailored to support clients in the biopharmaceutical industry. The firm's offerings include research, testing, and production services for biopharmaceutical products. The company's core business model revolves around delivering specialized services to clients in the life sciences sector. It targets pharmaceutical companies and biotech firms seeking to develop and produce cell and gene-based treatments. ENCell's quality testing services ensure regulatory compliance and product safety, while its consignment production supports clients in scaling manufacturing without capital investment. These services collectively address key needs in the biopharmaceutical development lifecycle. ENCell Co Ltd's revenue streams are derived from research contracts, testing service fees, and consignment production agreements. The company's clients include pharmaceutical and biotechnology firms that outsource their biopharmaceutical development and production needs. By focusing on cell and gene-based therapies, ENCell positions itself as a specialized partner for clients navigating the complexities of modern biopharmaceutical innovation. ENCell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ENCell Co stock

Total Assets per Share of ENCell Co is 7,244.71 KRW in 2025.

Total Assets per Share of ENCell Co changed from 6,338.69 KRW to 7,244.71 KRW, representing a 14.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share ENCell Co since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — ENCell Co

All Key Metrics — ENCell Co